Swixx BioPharma
LeaveRussia detail: Continue Operations
Swixx BioPharma is a specialized distributor of rare diseases, Rx and OTC medicinal products in Central & Eastern Europe, and acts as a true commercialization partner for Biotech & Pharma companies in this area.
Decision trail
Decision date 28/03/2023 · Reference ↗
The American company Eli Lilly will transfer its Russian business to the Swiss company Swixx Biopharma. Previously, Swixx Biopharma received the business of another American pharmaceutical company, Bristol-Myers Squibb (BMS). The American Eli Lilly banned the Swiss Swixx BioPharma, which a year ago bought Eli Lilly’s business in Russia, from supplying Humalog insulin to the country.
Status history since 2022
- 03/08/2026 — operating · Imported from KSE LeaveRussia
Exposure profile
Full exposure profile is a Professional feature
Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.
Upgrade to Professional